Selank and Anxiety: A Look at the Limited Human Data
A Russian-developed anxiolytic peptide with real clinical use there and very little independent replication.
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and studied there as an anti-anxiety agent. It circulates in nootropic and peptide communities as a calmer, non-sedating alternative to benzodiazepines. The interesting part is that it has actually been studied in patients in its country of origin. The cautionary part is how little independent, high-quality evidence exists outside that context.
What it is and what’s claimed
Selank is a stabilized analog of tuftsin, a naturally occurring immunomodulatory peptide. It is proposed to influence GABAergic and other neurotransmitter systems and to affect levels of leu-enkephalin, and it is claimed to reduce anxiety without the sedation, cognitive blunting, or dependence associated with benzodiazepines.
The most-cited human study is a 2008 randomized comparative trial by Zozulia, Neznamov and colleagues, published in the Russian journal Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PMID 18454096). It enrolled 62 patients with generalized anxiety disorder and neurasthenia, comparing Selank against the benzodiazepine medazepam.
The honest framing: the authors reported that Selank’s anxiolytic effect was similar to medazepam on the Hamilton, Zung and Clinical Global Impression scales, with added antiasthenic effects and less sedation. But this is one small trial in one country — not an independently replicated, Western-regulated evidence base.
Where the evidence falls short
The gap isn’t that studies don’t exist; it’s their scale, accessibility, and independence:
- Small samples. The flagship comparative trial had 62 patients total.
- Limited independent replication. The supporting literature is largely Russian-language and has not been reproduced in large blinded Western trials.
- Thin reporting in English. The English abstract of the 2008 study describes effects qualitatively; scale deltas, p-values, and responder rates are not laid out.
- Unregulated sourcing. Selank is approved as a medicine in Russia, but what is sold online to Western buyers is an unregulated research compound of uncertain purity and dose.
A measured stance
None of this proves Selank doesn’t work. It means the evidence base is too limited to make confident claims either way, and buying an unregulated compound adds practical risk on top of the scientific uncertainty.
The takeaway
Selank is more interesting than most peptides in its category precisely because it has a real clinical history — a small randomized trial reporting benzodiazepine-comparable anxiolysis with less sedation. But that history sits largely outside the independent, replicated research the rest of the world relies on. The honest verdict is genuine uncertainty: a plausible compound with suggestive data and too little rigorous, accessible evidence to recommend with confidence.